Minimal residual disease associated with overall survival in leukemia The Oncology Report Dr. Paolo Strati and his associates studied 237 chronic lymphocytic leukemia (CLL) patients who were undergoing first-line treatment with fludarabine, cyclophosphamide, and rituximab (FCR). Bone-marrow minimal residual disease (MRD) was measured by ... |
